EUCTR2012-005694-31-DE
Active, not recruiting
Not Applicable
Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study - APD-209 Eye drops phase IIa study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKC
- Sponsor
- Adenovir Pharma AB
- Enrollment
- 130
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men or women aged 18 years or above with onset of adenoviral EKC symptoms in at least one eye, as diagnosed according to current clinical practice, and with symptoms appearing within less than 7 days at the time of giving informed consent will be included in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 130
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1\) Known or suspected allergy to any ingredient of the IMP or placebo.
- •2\) Symptoms correlating with EKC since more than 7 days.
- •3\) Diagnosis of other significant disease(s) than EKC in the eye.
- •4\) Diagnosis of bacterial or fungal ocular infections, as assessed by the Investigator.
- •5\) Use of antibiotics or corticosteroids by any route (except intravitreal corticosteroids) within 14 days prior to inclusion. Ocular antibiotics may, however, be used until 2 hours prior to first dose of IMP, but are thereafter prohibited during the study.
- •6\) Use of immunosuppressive medications (including intravitreal corticosteroids) within 6 months prior to inclusion.
- •7\) Use of antiviral medications within 7 days prior to inclusion.
- •8\) Usage of any medication or herbal medicinal product with documented adverse reactions affecting the eyes, assessed by the Investigator as being relevant for the study.
- •9\) Usage of any medication or herbal medicinal product for ocular administration at inclusion.
- •10\) Female patients: currently pregnant or breast\-feeding or intending to become pregnant during the study period.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study - APD-209 Eye drops phase IIa studyAcute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKCMedDRA version: 18.1Level: LLTClassification code 10014975Term: Epidemic keratoconjunctivitisSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2012-005694-31-PLAdenovir Pharma AB47
Active, not recruiting
Not Applicable
Study comparing the efficacy of Eye drops containing the substance APD-209 and placebo for the treatment the a viral eye infection called Adenoviral-induced Epidemic Keratoconjunctivitis (EKC).Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKCMedDRA version: 14.1Level: LLTClassification code 10014975Term: Epidemic keratoconjunctivitisSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2012-005694-31-SEAdenovir Pharma AB130
Completed
Phase 2
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)Viral ConjunctivitisNCT01977443Adenovir Pharma AB47
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of AD-209Hypertension, EssentialNCT05631990Addpharma Inc.221
Not yet recruiting
Phase 1
ROLE OF CERTAIN TOPICAL AND SYSTEMIC AYURVEDIC DRUGS IN TONSILLITIS(TUNDIKERI).Health Condition 1: -CTRI/2018/09/015625ational Institute of Ayurveda